Tramiprosate nutraceutical planned
This article was originally published in The Tan Sheet
Executive Summary
Neurology drug developer Neurochem is creating a separate company to market a branded nutraceutical containing tramiprosate for Alzheimer's disease, with likely launch in 2008, after abandoning development of an Rx drug using the ingredient, the Canadian firm says Nov. 8. The decision to stop development of its oral beta-amyloid fibrillogenesis inhibitor Alzhemed comes after Neurochem announced in August that data from its Phase III North American trial showed no statistically significant difference in favor of Alzhemed versus placebo. Neurochem noted while tramiprosate did not show statistical significance in the primary endpoint in its North American trial, a preliminary post-hoc analysis, which allowed adjustment for potential confounding factors, showed a dose-dependent reduction in hippocampal atrophy in patients treated with tramiprosate versus placebo. The Laval, Quebec-based firm also said it plans to move a follow-on compound, NRM-8499, into preclinical development as an Rx product...
You may also be interested in...
Neurochem Faces Obstacles To Making Supplement Out Of Drug Candidate
Neurochem's plan to market a failed Alzheimer's disease drug candidate as a dietary supplement could stumble in the United States over requirements of the Dietary Supplement Health and Education Act, regulatory experts say
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.